Entero Therapeutics (ENTO) Competitors $0.34 0.00 (-0.21%) As of 12:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. AIM, AYTU, SNOA, NKGN, LIPO, ALBT, CPHI, GTBP, FRTX, and NLSPShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include AIM ImmunoTech (AIM), Aytu BioPharma (AYTU), Sonoma Pharmaceuticals (SNOA), NKGen Biotech (NKGN), Lipella Pharmaceuticals (LIPO), Avalon GloboCare (ALBT), China Pharma (CPHI), GT Biopharma (GTBP), Fresh Tracks Therapeutics (FRTX), and NLS Pharmaceutics (NLSP). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. AIM ImmunoTech Aytu BioPharma Sonoma Pharmaceuticals NKGen Biotech Lipella Pharmaceuticals Avalon GloboCare China Pharma GT Biopharma Fresh Tracks Therapeutics NLS Pharmaceutics Entero Therapeutics (NASDAQ:ENTO) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Do analysts prefer ENTO or AIM? AIM ImmunoTech has a consensus price target of $2.75, suggesting a potential upside of 2,908.75%. Given AIM ImmunoTech's stronger consensus rating and higher probable upside, analysts plainly believe AIM ImmunoTech is more favorable than Entero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ENTO or AIM? AIM ImmunoTech received 59 more outperform votes than Entero Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformEntero TherapeuticsN/AN/AAIM ImmunoTechOutperform Votes5983.10% Underperform Votes1216.90% Which has preferable earnings & valuation, ENTO or AIM? Entero Therapeutics has higher earnings, but lower revenue than AIM ImmunoTech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntero TherapeuticsN/AN/A-$15.80MN/AN/AAIM ImmunoTech$170K38.87-$28.96M-$0.31-0.29 Does the media prefer ENTO or AIM? In the previous week, Entero Therapeutics had 2 more articles in the media than AIM ImmunoTech. MarketBeat recorded 2 mentions for Entero Therapeutics and 0 mentions for AIM ImmunoTech. Entero Therapeutics' average media sentiment score of 0.44 beat AIM ImmunoTech's score of -0.76 indicating that Entero Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Entero Therapeutics Neutral AIM ImmunoTech Negative Do insiders and institutionals have more ownership in ENTO or AIM? 12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 0.5% of Entero Therapeutics shares are held by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, ENTO or AIM? Entero Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Is ENTO or AIM more profitable? Entero Therapeutics has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Entero Therapeutics' return on equity of -87.06% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets Entero TherapeuticsN/A -87.06% -12.01% AIM ImmunoTech -12,594.21%-421.73%-147.54% SummaryEntero Therapeutics beats AIM ImmunoTech on 9 of the 14 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.62M$6.79B$5.53B$7.99BDividend YieldN/A3.05%5.11%4.23%P/E RatioN/A7.4422.6518.64Price / SalesN/A244.75401.98103.80Price / CashN/A65.8538.1834.62Price / Book0.156.536.754.30Net Income-$15.80M$143.43M$3.22B$248.44M7 Day Performance-9.69%2.23%1.66%1.81%1 Month Performance-17.09%7.19%4.17%4.40%1 Year PerformanceN/A-2.24%16.17%5.97% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero Therapeutics0.2722 of 5 stars$0.34-0.2%N/AN/A$1.62MN/A0.009Gap DownAIMAIM ImmunoTech1.682 of 5 stars$0.09-22.3%$2.75+2,908.8%-77.6%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeAYTUAytu BioPharma1.691 of 5 stars$1.07-1.4%N/A-52.0%$6.60M$77.23M-0.74160Positive NewsSNOASonoma Pharmaceuticals1.0154 of 5 stars$3.95+0.3%N/A+2,291.4%$6.38M$13.97M-0.98180Gap DownNKGNNKGen BiotechN/A$0.14-6.6%N/A-89.1%$6.30M$80,000.00-0.03N/AGap UpLIPOLipella Pharmaceuticals2.4561 of 5 stars$2.45-6.8%N/A-57.3%$6.25M$536,357.00-0.584Upcoming EarningsGap DownALBTAvalon GloboCare0.9525 of 5 stars$3.74-7.7%N/A-9.3%$6.18M$1.31M-0.195Short Interest ↑News CoverageCPHIChina PharmaN/A$1.88-4.1%N/A-93.0%$6.13M$4.53M0.00250GTBPGT Biopharma3.5018 of 5 stars$2.30flat$11.00+378.3%-19.3%$5.83MN/A-0.338Short Interest ↓Positive NewsGap DownFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+2.7%$5.59M$10.06M-0.6620NLSPNLS PharmaceuticsN/A$1.53+3.7%N/A+953.7%$5.49MN/A0.006 Related Companies and Tools Related Companies AIM ImmunoTech Competitors Aytu BioPharma Competitors Sonoma Pharmaceuticals Competitors NKGen Biotech Competitors Lipella Pharmaceuticals Competitors Avalon GloboCare Competitors China Pharma Competitors GT Biopharma Competitors Fresh Tracks Therapeutics Competitors NLS Pharmaceutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENTO Stock Free ENTO Stock Alerts